UPPSALA, Sweden, Nov. 12 /CNW/ - Beactica AB announced today that it has
entered into a drug discovery collaboration agreement with Arrow Therapeutics
Ltd (London, UK) whereby Beactica will direct its novel characterisation
technology at selected Arrow compounds against a confidential target.
(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/281137 )
"We are very pleased to be working with Arrow" said Beactica's CEO, Dr
Per Kallblad. "The company has a world-class reputation for conducting break
through research in the antiviral field and we look forward to applying our
technology on their targets."
CEO of Arrow Therapeutics, Dr Ken Powell, said "Working with Beactica
provides us with an opportunity to apply a new technology that has already
shown strong potential."
Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the biophysical interaction of molecules
in order to generate novel therapeutics. As well as building collaborations
with external companies, Beactica is progressing its own drug discovery
For more information about Beactica, please visit
About Arrow Therapeutics
Arrow Therapeutics Ltd is a fully integrated pharmaceutical company,
focused exclusively on the discovery and development of novel antiviral
therapeutics in areas of significant unmet need. Established in 1998 and
acquired by AstraZeneca in February 2007, Arrow specialises in small molecule
drugs with novel mechanisms of action. The company has a number of research
and development programs, the most advanced of which target Respiratory
Syncytial Virus (RSV) and Hepatitis C Virus (HCV).
For more information about Arrow Therapeutics, please visit
For further information:
For further information: Dr Per Kallblad, CEO Beactica,
+46(0)730-674488, or Dr Ken Powell, CEO Arrow Therapeutics, +44(0)207015-1000